← Back to Analyst Consensus 
AVTX Buy
Avalo Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 20
30-Day Momentum
▲ 0 upgrades / ▼ 2 downgrades / 2 reiterations from 4 firms
Next Earnings
Nov 4, 2026 (9 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 23, 2026 | Guggenheim | downgrade | Buy → Neutral | — | 52% |
| Oct 23, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Oct 23, 2026 | HC Wainwright & Co. | downgrade | Buy → Neutral | — | 44% |
| Oct 23, 2026 | BTIG | maintain | Buy → Buy | — | 52% |
| Aug 7, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Aug 7, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Jul 6, 2026 | Leerink Partners | initiate | — → Outperform | — | 51% |
| Jun 16, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Jun 12, 2026 | B of A Securities | initiate | — → Buy | — | 53% |
| May 14, 2026 | Citizens | maintain | Market Outperform → Market Outperform | — | 46% |
| May 14, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| May 14, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| May 14, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| May 11, 2026 | Piper Sandler | maintain | Overweight → Overweight | — | 54% |
| May 6, 2026 | Citizens | maintain | Market Outperform → Market Outperform | — | 46% |
| May 6, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| May 6, 2026 | BTIG | maintain | Buy → Buy | — | 52% |
| Apr 13, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Apr 9, 2026 | Wolfe Research | initiate | — → Outperform | — | 53% |
| Apr 6, 2026 | Citizens | initiate | — → Market Outperform | — | 46% |
| Mar 25, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Mar 24, 2026 | BTIG | reiterate | Buy → Buy | — | 52% |
| Feb 2, 2026 | Guggenheim | initiate | — → Buy | $50 | 52% |
| Jan 15, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | $25 | 44% |
| Dec 18, 2025 | Mizuho | initiate | — → Outperform | $39 | 52% |
| Sep 29, 2025 | BTIG | reiterate | Buy → Buy | $40 | 52% |
| Sep 17, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $25 | 44% |
| Aug 15, 2025 | Cantor Fitzgerald | initiate | — → Overweight | $0 | 50% |
| Mar 25, 2025 | Jefferies | initiate | — → Buy | $23 | 52% |
| Mar 25, 2025 | Stifel | initiate | — → Buy | $36 | 53% |
| Mar 20, 2025 | HC Wainwright & Co. | reiterate | Neutral → Neutral | $0 | 44% |
| Feb 28, 2025 | Piper Sandler | initiate | — → Overweight | $48 | 54% |
| Dec 19, 2024 | BTIG | initiate | — → Buy | $40 | 52% |
| Dec 17, 2024 | LUCID CAPITAL MARKETS | initiate | — → Buy | $24 | 34% |
| Oct 24, 2024 | HC Wainwright & Co. | initiate | — → Neutral | $0 | 44% |
| Apr 16, 2024 | Oppenheimer | upgrade | Perform → Outperform | $35 | 52% |
Price Target Trend
May 26, 2026 Latest: $38.5 Oct 25, 2026
EPS Estimates
+1q $-0.52
Lo: $-0.70 Hi: $-0.39
8 analysts ▲3
0y $-2.73
Lo: $-3.06 Hi: $-2.18
8 analysts ▲3
0q $-0.56
Lo: $-0.66 Hi: $-0.45
8 analysts ▲3
+1y $-2.71
Lo: $-4.10 Hi: $-1.33
10 analysts ▲3
Cross-Platform Signals
No cross-platform signals in the last 90 days